JP6738316B2 - 粘度を低下させるためのｔｒｅｍ−１抗体の部位特異的変異誘発 - Google Patents

粘度を低下させるためのｔｒｅｍ−１抗体の部位特異的変異誘発 Download PDF

Info

Publication number
JP6738316B2
JP6738316B2 JP2017502703A JP2017502703A JP6738316B2 JP 6738316 B2 JP6738316 B2 JP 6738316B2 JP 2017502703 A JP2017502703 A JP 2017502703A JP 2017502703 A JP2017502703 A JP 2017502703A JP 6738316 B2 JP6738316 B2 JP 6738316B2
Authority
JP
Japan
Prior art keywords
amino acid
seq
antibody
glutamine
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017502703A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017522325A (ja
JP2017522325A5 (enExample
Inventor
アネデ・ヘンリクセン
クリスティアン・ケアゴー
ヴィベケ・ヴェストファール・ステニケ
シャロデ・ヴィーベア
Original Assignee
ノヴォ ノルディスク アクティーゼルスカブ
ノヴォ ノルディスク アクティーゼルスカブ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53673951&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6738316(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP14177547.8A external-priority patent/EP2975056A1/en
Priority claimed from EP14194893.5A external-priority patent/EP3026061A1/en
Application filed by ノヴォ ノルディスク アクティーゼルスカブ, ノヴォ ノルディスク アクティーゼルスカブ filed Critical ノヴォ ノルディスク アクティーゼルスカブ
Publication of JP2017522325A publication Critical patent/JP2017522325A/ja
Publication of JP2017522325A5 publication Critical patent/JP2017522325A5/ja
Application granted granted Critical
Publication of JP6738316B2 publication Critical patent/JP6738316B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2017502703A 2014-07-17 2015-07-17 粘度を低下させるためのｔｒｅｍ−１抗体の部位特異的変異誘発 Active JP6738316B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP14177547.8A EP2975056A1 (en) 2014-07-17 2014-07-17 Site directed mutagenesis of TREM-1 antibodies for decreasing viscosity
EP14177547.8 2014-07-17
EP14194893.5 2014-11-26
EP14194893.5A EP3026061A1 (en) 2014-11-26 2014-11-26 Site directed mutagenesis of trem-1 antibodies for decreasing viscosity.
PCT/EP2015/066501 WO2016009086A1 (en) 2014-07-17 2015-07-17 Site directed mutagenesis of trem-1 antibodies for decreasing viscosity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020122759A Division JP6995170B2 (ja) 2014-07-17 2020-07-17 粘度を低下させるためのｔｒｅｍ－１抗体の部位特異的変異誘発

Publications (3)

Publication Number Publication Date
JP2017522325A JP2017522325A (ja) 2017-08-10
JP2017522325A5 JP2017522325A5 (enExample) 2018-09-13
JP6738316B2 true JP6738316B2 (ja) 2020-08-12

Family

ID=53673951

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017502703A Active JP6738316B2 (ja) 2014-07-17 2015-07-17 粘度を低下させるためのｔｒｅｍ−１抗体の部位特異的変異誘発
JP2020122759A Active JP6995170B2 (ja) 2014-07-17 2020-07-17 粘度を低下させるためのｔｒｅｍ－１抗体の部位特異的変異誘発

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020122759A Active JP6995170B2 (ja) 2014-07-17 2020-07-17 粘度を低下させるためのｔｒｅｍ－１抗体の部位特異的変異誘発

Country Status (29)

Country Link
US (4) US10179814B2 (enExample)
EP (2) EP3172232B1 (enExample)
JP (2) JP6738316B2 (enExample)
KR (4) KR20250110365A (enExample)
CN (2) CN106536559B (enExample)
AU (1) AU2015289054B2 (enExample)
CA (1) CA2955253C (enExample)
CL (1) CL2017000113A1 (enExample)
CO (1) CO2017001397A2 (enExample)
DK (1) DK3172232T5 (enExample)
EA (1) EA037844B1 (enExample)
ES (1) ES2974575T3 (enExample)
FI (1) FI3172232T3 (enExample)
HR (1) HRP20240088T1 (enExample)
HU (1) HUE065807T2 (enExample)
IL (1) IL250082B (enExample)
LT (1) LT3172232T (enExample)
MX (2) MX378492B (enExample)
MY (1) MY178347A (enExample)
PE (1) PE20170192A1 (enExample)
PH (1) PH12017500054A1 (enExample)
PL (1) PL3172232T3 (enExample)
RS (1) RS65136B1 (enExample)
SG (2) SG11201700250WA (enExample)
SI (1) SI3172232T1 (enExample)
SM (1) SMT202400072T1 (enExample)
TN (1) TN2017000008A1 (enExample)
WO (1) WO2016009086A1 (enExample)
ZA (1) ZA201700341B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
BR112015023510A2 (pt) 2013-03-15 2017-10-10 Fundacio Inst De Recerca Biomedica Irb Barcelona método para o diagnóstico, prognóstico e tratamento de câncer metastático
KR20250110365A (ko) 2014-07-17 2025-07-18 노보 노르디스크 에이/에스 점도를 감소시키기 위한 trem-1 항체의 부위 지정 돌연변이유발
US11472877B2 (en) 2016-03-04 2022-10-18 Alector Llc Anti-TREM1 antibodies and methods of use thereof
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
EP3664845A4 (en) * 2017-08-08 2021-03-10 Pionyr Immunotherapeutics, Inc. COMPOSITIONS AND METHODS FOR DEACTIVATING MEYLOID CELLS EXPRESSING TREM1
CR20250022A (es) * 2018-04-02 2025-02-25 Bristol Myers Squibb Co Anticuerpos anti-trem-1, ácidos nucleicos y vectores de los mismos (divisional 2020-0450)
US10836828B2 (en) 2019-02-06 2020-11-17 Pionyr Immunotherapeutics, Inc. Anti-TREM1 antibodies and related methods
JP2022540904A (ja) * 2019-07-15 2022-09-20 ブリストル－マイヤーズ スクイブ カンパニー ヒトｔｒｅｍ－１に対する抗体およびその使用
WO2021011678A1 (en) 2019-07-15 2021-01-21 Bristol-Myers Squibb Company Anti-trem-1 antibodies and uses thereof
TW202204594A (zh) 2020-04-20 2022-02-01 日商三得利控股股份有限公司 包含甜菊醇醣苷之酒精飲料
CN115586338A (zh) * 2022-09-20 2023-01-10 杭州赛基生物科技有限公司 用于检测可溶性细胞因子受体的试剂盒及其制备方法
CN120958031A (zh) 2023-04-21 2025-11-14 赛斯尔斯治疗公司 抗trem1抗体药剂、组合物及其用途

Family Cites Families (179)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JP2874751B2 (ja) 1986-04-09 1999-03-24 ジェンザイム・コーポレーション 希望する蛋白質をミルク中へ分泌する遺伝子移植動物
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JP2972257B2 (ja) 1990-01-24 1999-11-08 株式会社日立製作所 パケット交換機
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP1997891A1 (en) 1988-09-02 2008-12-03 Dyax Corporation Generation and selection of recombinant varied binding proteins
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5459039A (en) 1989-05-12 1995-10-17 Duke University Methods for mapping genetic mutations
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5272071A (en) 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
IL98764A0 (en) 1990-07-10 1992-07-15 Smithkline Beecham Corp Oxamides
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
CA2092323A1 (en) 1990-10-01 1992-04-02 George Y. Wu Targeting viruses and cells for selective internalization by cells
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
DE69233750D1 (de) 1991-04-10 2009-01-02 Scripps Research Inst Bibliotheken heterodimerer Rezeptoren mittels Phagemiden
DE69231736T2 (de) 1991-05-14 2001-10-25 The Immune Response Corp., Carlsbad Gerichtete abgabe von genen, die immunogene proteine kodieren
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
DE69231385T2 (de) 1991-06-05 2001-04-12 The Board Of Regents Acting For And On Behalf Of The Unversity Of Michigan, Ann Arbor Zielgerichtete freisetzung von genen, die sekretorische proteine kodieren
WO1992022324A1 (en) 1991-06-14 1992-12-23 Xoma Corporation Microbially-produced antibody fragments and their conjugates
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
ATE408012T1 (de) 1991-12-02 2008-09-15 Medical Res Council Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
WO1993014188A1 (en) 1992-01-17 1993-07-22 The Regents Of The University Of Michigan Targeted virus
US5424288A (en) 1992-02-28 1995-06-13 Order; Stanley E. Method of treating solid tumor cancers utilizing macro aggregated proteins and colloidal radioactive phosphorous
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1993020221A1 (en) 1992-04-03 1993-10-14 Young Alexander T Gene therapy using targeted viral vectors
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
FR2694851B1 (fr) 1992-08-12 1994-12-23 Sgs Thomson Microelectronics Circuit de tirage vers un état déterminé d'une entrée de circuit intégré.
EP0749475A4 (en) 1992-08-26 1997-05-07 Harvard College USE OF CYTOKINE IP-10 AS ANTI-TUMOR AGENT
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
CA2146747C (en) 1992-10-09 2006-12-19 Brian A. Naughton Liver reserve cells
DE69333366T2 (de) 1992-10-30 2004-09-16 The General Hospital Corp., Boston Ein neues zellzyklus kontrollprotein
CA2592997A1 (en) 1992-12-03 1994-06-09 Genzyme Corporation Pseudo-adenovirus vectors
DE69433811T2 (de) 1993-01-07 2005-06-23 Sequenom, Inc., San Diego Dns - sequenzierung durch massenspektronomie
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5498531A (en) 1993-09-10 1996-03-12 President And Fellows Of Harvard College Intron-mediated recombinant techniques and reagents
WO1995015982A2 (en) 1993-12-08 1995-06-15 Genzyme Corporation Process for generating specific antibodies
DK1231268T3 (da) 1994-01-31 2005-11-21 Univ Boston Polyklonale antistofbiblioteker
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
JP4312259B2 (ja) 1995-04-27 2009-08-12 アムジェン フレモント インク． 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
GB9517780D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
GB9517779D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
ES2283025T3 (es) 1996-08-30 2007-10-16 Novo Nordisk A/S Derivados de glp-1.1.
US6034217A (en) 1996-09-17 2000-03-07 Wako Pure Chemical Industries, Ltd. Peptidoglycan recognition proteins and their production
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
DE69738539T2 (de) 1996-12-03 2009-03-26 Amgen Fremont Inc. Vollkommen humane Antikörper die EGFR binden
US20030049618A1 (en) 1997-03-07 2003-03-13 Ruben Steven M. 186 human secreted proteins
US20030175858A1 (en) 1997-03-07 2003-09-18 Ruben Steven M. 186 human secreted proteins
US6420526B1 (en) 1997-03-07 2002-07-16 Human Genome Sciences, Inc. 186 human secreted proteins
CA2283299A1 (en) 1997-03-07 1998-09-11 Human Genome Sciences, Inc. 186 human secreted proteins
US6878687B1 (en) 1997-03-07 2005-04-12 Human Genome Sciences, Inc. Protein HMAAD57
WO1998039446A2 (en) 1997-03-07 1998-09-11 Human Genome Sciences, Inc. 70 human secreted proteins
BRPI9809391B8 (pt) 1997-04-14 2021-05-25 Amgen Res Munich Gmbh processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica
WO1998048837A1 (en) 1997-04-30 1998-11-05 Enzon, Inc. Polyalkylene oxide-modified single chain polypeptides
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6172211B1 (en) 1997-07-11 2001-01-09 Boehringer Ingelheim International Gmbh Nucleic acid encoding tag7 polypeptide
EP1375515A3 (en) 1997-10-07 2004-04-21 Ono Pharmaceutical Co., Ltd. Polypeptide, cDNA encoding the same, and use thereof
EP1090118A2 (en) 1998-06-26 2001-04-11 Incyte Pharmaceuticals, Inc. Human signal peptide-containing proteins
US20020197669A1 (en) 2000-12-13 2002-12-26 Bangur Chaitanya S. Compositions and methods for the therapy and diagnosis of lung cancer
US20020172952A1 (en) 1999-06-30 2002-11-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6858204B2 (en) 1999-06-30 2005-02-22 Corxia Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6504010B1 (en) 1999-06-30 2003-01-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6509448B2 (en) 1999-06-30 2003-01-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030170255A1 (en) 1999-06-30 2003-09-11 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030211510A1 (en) 1999-06-30 2003-11-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
CA2402563A1 (en) 1999-12-23 2001-07-26 Hyseq, Inc. Novel nucleic acids and polypeptides
AU2001274888A1 (en) 2000-05-19 2001-12-03 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US20030134283A1 (en) 2000-10-03 2003-07-17 Peterson David P. Genes regulated in dendritic cell differentiation
US7858094B2 (en) 2000-12-08 2010-12-28 Geneprint Corporation TREM-1 splice variant for use in modifying immune responses
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
CA2342376C (en) 2001-03-20 2013-11-12 Marco Colonna A receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
US8231878B2 (en) 2001-03-20 2012-07-31 Cosmo Research & Development S.P.A. Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US20040236092A1 (en) 2001-07-13 2004-11-25 Roman Dziarski Peptidologlycan recognition protein encoding nucleic acids and methods of use thereof
EP1434881A4 (en) 2001-09-17 2005-10-26 Protein Design Labs Inc METHOD FOR DIAGNOSIS OF CANCER COMPOSITIONS AND METHOD FOR SCREENING ON CANCER MODULATORS
AU2002334997A1 (en) 2001-10-12 2003-04-22 Schering Corporation Use of bispecific antibodies to regulate immune responses
AU2002364586A1 (en) 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
EP1329227A1 (en) 2002-01-22 2003-07-23 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Diagnostic conjugate useful for intercellular imaging and for differentiating between tumor- and non-tumor cells
AU2003215761A1 (en) 2002-03-22 2003-10-08 Bioxell S.P.A. A novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
AU2003265787A1 (en) 2002-08-29 2004-03-19 Five Prime Therapeutics, Inc. Methods of use for novel human polypeptides encoded by polynucleotides
GB0305478D0 (en) 2003-03-10 2003-04-16 Bioxell Spa Diagnostic and prognostic compounds and method
US20050255114A1 (en) 2003-04-07 2005-11-17 Nuvelo, Inc. Methods and diagnosis for the treatment of preeclampsia
DE10316701A1 (de) 2003-04-09 2004-11-04 Hinzmann, Bernd, Dr. Humane Nukleinsäuresequenzen aus Bronchialkarzinomen
KR20060031809A (ko) 2003-06-09 2006-04-13 더 리젠츠 오브 더 유니버시티 오브 미시간 암 치료 및 진단용 조성물 및 방법
JP2007534631A (ja) 2003-10-28 2007-11-29 ノボ　ノルディスク　アクティーゼルスカブ ラミニン−５γ２結合性ペプチド、その関連組成物およびその使用
EP1692506A4 (en) 2003-11-17 2008-01-09 Janssen Pharmaceutica Nv MODELING A SYSTEMIC INFLAMMATORY RESPONSE TO INFECTION
GB0401730D0 (en) 2004-01-27 2004-03-03 Bioxell Spa Diagnosis method
JP2007531715A (ja) 2004-03-17 2007-11-08 イーライ リリー アンド カンパニー グリコール結合ｆｇｆ−２１化合物
US7576190B2 (en) 2004-05-13 2009-08-18 Eli Lilly And Company FGF-21 fusion proteins
US7622445B2 (en) 2004-09-02 2009-11-24 Eli Lilly And Company Muteins of fibroblast growth factor 21
ATE444307T1 (de) 2004-09-02 2009-10-15 Lilly Co Eli Muteine des fibroblasten-wachstumsfaktors 21
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
JP2008522617A (ja) 2004-12-14 2008-07-03 イーライ リリー アンド カンパニー 線維芽細胞成長因子２１の突然変異タンパク質
EP1846019A2 (en) 2005-01-21 2007-10-24 Eli Lilly And Company Method for treating cardiovascular disease
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
US20070099209A1 (en) 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2006138275A2 (en) 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
EP2076272B1 (en) 2006-10-19 2015-07-29 Baylor College Of Medicine Generating an immune response by inducing cd40 and pattern recognition receptors
WO2008088849A2 (en) 2007-01-16 2008-07-24 Wyeth Inflammation treatment, detection and monitoring via trem-1
JP2010523084A (ja) 2007-03-30 2010-07-15 アンブルックス，インコーポレイテッド 修飾ｆｇｆ−２１ポリペプチド
EP2626371A1 (en) 2007-07-31 2013-08-14 MedImmune, LLC Multispecific epitope binding proteins and uses thereof
EP2185178B1 (en) 2007-08-03 2017-08-23 Eli Lilly And Company Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity
BRPI0815416A2 (pt) 2007-08-15 2014-10-21 Amunix Inc Composições e métodos para modificar propriedades de polipeptídeos biologicamente ativos
WO2009030771A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
CN101946180B (zh) 2007-12-19 2013-11-13 神谷来克斯公司 单分子检测用扫描分析器和使用方法
CN102016552A (zh) 2008-03-05 2011-04-13 神谷来克斯公司 用于分子的高灵敏性检测的方法和组合物
ES2506116T3 (es) 2008-05-23 2014-10-13 Biocartis Nv Nuevo biomarcador para diagnóstico, predicción y/o pronóstico de septicemia y usos del mismo
AU2009268585C1 (en) 2008-07-08 2014-10-02 Abbvie Inc. Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
EP2326731B1 (en) 2008-08-25 2013-11-13 Janssen Biotech, Inc. Biomarkers for anti-tnf treatment in ulcerative colitis and related disorders
EP2358749B1 (en) 2008-10-10 2018-07-18 Amgen, Inc Fgf21 mutants and uses thereof
WO2010065439A1 (en) 2008-12-05 2010-06-10 Eli Lilly And Company Variants of fibroblast growth factor 21
CN102361647B (zh) 2009-01-23 2018-02-16 诺沃-诺迪斯克有限公司 具有白蛋白结合剂a‑b‑c‑d‑e‑的fgf21衍生物及其应用
WO2010132370A2 (en) 2009-05-11 2010-11-18 Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Soluble tlt-1 for the treatment and diagnosis of sepsis
WO2010141469A2 (en) 2009-06-01 2010-12-09 Case Western Reserve University Protein biomarkers and therapeutic targets for autoimmune and alloimmune diseases
WO2010142665A1 (en) 2009-06-11 2010-12-16 Novo Nordisk A/S Glp-1 and fgf21 combinations for treatment of diabetes type 2
US20120213705A1 (en) 2009-06-22 2012-08-23 Medimmune, Llc ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
WO2011047097A2 (en) 2009-10-13 2011-04-21 Sigalov Alexander B Inhibition of trem receptor signaling with peptide variants
KR101251023B1 (ko) 2009-11-05 2013-04-03 주식회사유한양행 신규한 단일클론항체를 포함하는 박테리아 감염 검출용 키트
JP6184695B2 (ja) 2009-12-04 2017-08-23 ジェネンテック， インコーポレイテッド 多重特異性抗体、抗体アナログ、組成物、及び方法
WO2011091078A2 (en) 2010-01-19 2011-07-28 Xencor, Inc. Antibody fc variants with enhanced complement activity
CA2798120A1 (en) 2010-04-30 2011-11-03 Paul P. Tamburini Antibodies having reduced immunogenicity in a human
US20130330350A1 (en) 2010-11-09 2013-12-12 Medimmune, Llc Antibody Scaffold For Homogenous Conjugation
WO2012088290A2 (en) 2010-12-22 2012-06-28 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
WO2012088302A2 (en) 2010-12-22 2012-06-28 Abbott Laboratories Half immunoglobulin binding proteins and uses thereof
CA2827170A1 (en) 2011-02-11 2012-08-16 David M. Hilbert Monovalent and multivalent multispecific complexes and uses thereof
HRP20190044T1 (hr) 2011-09-23 2019-02-22 Oncomed Pharmaceuticals, Inc. Agensi koji vežu vegf/dll4 i njihove uporabe
PL2814844T3 (pl) * 2012-02-15 2017-12-29 Novo Nordisk A/S Przeciwciała wiążące i blokujące receptor aktywujący wykazujący ekspresję na komórkach szpikowych -1 (trem-1)
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
MY188825A (en) * 2012-05-18 2022-01-06 Genentech Inc High-concentration monoclonal antibody formulations
SG11201408538PA (en) * 2012-07-13 2015-02-27 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
AU2013343099A1 (en) * 2012-11-09 2015-05-14 Pfizer Inc. Platelet-derived growth factor B specific antibodies and compositions and uses thereof
US10081681B2 (en) 2013-09-20 2018-09-25 Bristol-Myers Squibb Company Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors
KR20250110365A (ko) 2014-07-17 2025-07-18 노보 노르디스크 에이/에스 점도를 감소시키기 위한 trem-1 항체의 부위 지정 돌연변이유발
CR20250022A (es) * 2018-04-02 2025-02-25 Bristol Myers Squibb Co Anticuerpos anti-trem-1, ácidos nucleicos y vectores de los mismos (divisional 2020-0450)

Also Published As

Publication number Publication date
DK3172232T3 (da) 2024-02-12
FI3172232T3 (fi) 2024-03-19
JP6995170B2 (ja) 2022-01-14
AU2015289054A1 (en) 2017-03-09
PH12017500054A1 (en) 2017-05-22
US20220010012A1 (en) 2022-01-13
EP4332119A3 (en) 2024-05-29
HK1232231A1 (en) 2018-01-05
EP4332119A2 (en) 2024-03-06
KR20220156093A (ko) 2022-11-24
MY178347A (en) 2020-10-08
US11072654B2 (en) 2021-07-27
ZA201700341B (en) 2024-10-30
KR20250110365A (ko) 2025-07-18
CO2017001397A2 (es) 2017-05-10
SG10201913702WA (en) 2020-03-30
EA037844B1 (ru) 2021-05-27
HRP20240088T1 (hr) 2024-04-12
JP2017522325A (ja) 2017-08-10
US20170298130A1 (en) 2017-10-19
CL2017000113A1 (es) 2017-09-15
NZ766184A (en) 2024-08-30
WO2016009086A1 (en) 2016-01-21
ES2974575T3 (es) 2024-06-27
CN113214397A (zh) 2021-08-06
HUE065807T2 (hu) 2024-06-28
MX2020013920A (es) 2021-03-02
KR102833621B1 (ko) 2025-07-14
CN106536559B (zh) 2021-04-27
DK3172232T5 (en) 2024-11-18
MX378492B (es) 2025-03-11
KR102465120B1 (ko) 2022-11-10
CA2955253C (en) 2023-03-07
KR20170028439A (ko) 2017-03-13
MX2017000484A (es) 2017-05-01
US20190185560A1 (en) 2019-06-20
JP2020188786A (ja) 2020-11-26
EP3172232B1 (en) 2023-12-27
IL250082B (en) 2021-07-29
IL250082A0 (en) 2017-03-30
PL3172232T3 (pl) 2024-06-24
NZ766279A (en) 2024-08-30
PE20170192A1 (es) 2017-03-16
SMT202400072T1 (it) 2024-03-13
TN2017000008A1 (en) 2018-07-04
LT3172232T (lt) 2024-02-12
EP3172232A1 (en) 2017-05-31
KR102641268B1 (ko) 2024-02-27
US10179814B2 (en) 2019-01-15
CA2955253A1 (en) 2016-01-21
RS65136B1 (sr) 2024-02-29
SG11201700250WA (en) 2017-02-27
US12116408B2 (en) 2024-10-15
US20250034249A1 (en) 2025-01-30
NZ729121A (en) 2024-08-30
BR112016030947A2 (pt) 2017-10-24
KR20240029114A (ko) 2024-03-05
AU2015289054B2 (en) 2021-04-08
EA201790104A1 (ru) 2017-06-30
CN106536559A (zh) 2017-03-22
SI3172232T1 (sl) 2024-05-31

Similar Documents

Publication Publication Date Title
JP6995170B2 (ja) 粘度を低下させるためのｔｒｅｍ－１抗体の部位特異的変異誘発
JP6740308B2 (ja) 骨髄細胞で発現されるトリガー受容体１（ｔｒｅｍ−１）に結合し、それを遮断する抗体
US20210253697A1 (en) Methods of treating autoimmune disease or chronic inflammation with antibodies that bind and block triggering receptor expressed on myeloid cells-1 (trem-1)
EP3026061A1 (en) Site directed mutagenesis of trem-1 antibodies for decreasing viscosity.
EP2975056A1 (en) Site directed mutagenesis of TREM-1 antibodies for decreasing viscosity
HK40104795A (en) Site directed mutagenesis of trem-1 antibodies for decreasing viscosity
HK1232231B (en) Site directed mutagenesis of trem-1 antibodies for decreasing viscosity
BR112016030947B1 (pt) Anticorpo ou fragmento do mesmo que é capaz de se ligar e bloquear trem-1 e seus usos

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170317

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180713

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180801

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190531

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190611

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190906

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191111

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200519

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200617

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200717

R150 Certificate of patent or registration of utility model

Ref document number: 6738316

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250